Open AccessPressure‐and dose‐controlled, needle‐free, transcutaneous pneumatic injection of botulinum neurotoxin‐A for the treatment of primary axillary and palmoplantar hyperhidrosis
Author(s) -
Kim Hyoung Moon,
Lee Min Ji,
Lee Min Ho,
Lee Hwangheui
Publication year - 2020
Publication title -
skin research and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.521
H-Index - 69
eISSN - 1600-0846
pISSN - 0909-752X
DOI - 10.1111/srt.12835
Subject(s) - medicine , hyperhidrosis , anesthesia , axilla , botulinum neurotoxin , surgery , breast cancer , biochemistry , chemistry , cancer , toxin
Background Botulinum neurotoxin (BoNT) effectively downregulates the secretion of eccrine sweat glands in patients with axillary and palmoplantar primary hyperhidrosis (PH). Objective To demonstrate the efficacy and safety of pressure‐ and dose‐controlled, needle‐free, transcutaneous pneumatic injection (TPI) of BoNT‐A for treating axillary and palmoplantar PH. Methods Needleless TPI‐BoNT‐A treatments were delivered on the axillary or palmoplantar skin at a pneumatic pressure of 2.05 bars and an injection volume of 0.08 mL/shot. The efficacy thereof was assessed by evaluating starch‐iodine test results and Hyperhidrosis Disease Severity Scale (HDSS) scores. Results At baseline, median HDSS scores were 3 (IQR, 3‐4) for axillary lesions and 4 (IQR, 3.5‐4) for palmoplantar lesions. Median HDSS scores at 1 month after TPI‐BoNT‐A treatment significantly decreased to 1 (IQR, 1‐1.75) for axillary lesions ( P < .001) and 1 (IQR, 1‐2) for palmoplantar lesions ( P < .001). Median global improvement scale scores were 4 (IQR, 3.25‐4) for axillary PH and 3 (IQR, 2.5‐4) for palmoplantar PH ( P > .05). In all patients, pain was tolerable during treatments for both axillary and palmoplantar PH after the application of topical anesthetic cream. Conclusion Pressure‐ and dose‐controlled, needle‐free, BoNT delivery effectively and safely decreased sweating in axillary and palmoplantar skin.